Ionis EVP buys 376 shares in stock plan

Ionis Pharmaceuticals executive Patrick R. O'Neil acquired additional common shares through an employee stock purchase plan.

Accepted by SEC EDGAR 03/03/2026 - 05:29 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Ionis Pharmaceuticals executive Patrick R. O'Neil acquired additional common shares through an employee stock purchase plan. On February 27, 2026, he purchased 376 shares of Ionis common stock at an average price of $48.8665 per share under the Amended and Restated 2000 Employee Stock Purchase Plan. Following this transaction, his direct holdings increased to 72,359 common shares, and the newly purchased shares cannot be sold until August 27, 2026.

Insider Trade Summary

Other: 376 shares

Other 1 txn

Insider O'NEIL PATRICK R.

Role EVP CLO & General Counsel

Type	Security	Shares	Price	Value
Other	Common Stock	376	$48.8665	$18K

Holdings After Transaction: Common Stock — 72,359 shares (Direct)

Footnotes (1)

1. F1. Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on February 27, 2026. These shares may not be sold until August 27, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Ionis Pharmaceuticals (IONS) executive Patrick O'Neil report on this Form 4?

Patrick R. O'Neil reported acquiring 376 shares of Ionis common stock. The shares were purchased through the company’s Amended and Restated 2000 Employee Stock Purchase Plan on February 27, 2026, at an average price of $48.8665 per share.

At what price were the new Ionis (IONS) shares acquired under the stock purchase plan?

The newly acquired Ionis shares were purchased at an average price of $48.8665 per share. This price reflects the cost per share under the Amended and Restated 2000 Employee Stock Purchase Plan on February 27, 2026, as disclosed in the Form 4 filing.

How many Ionis Pharmaceuticals (IONS) shares does Patrick O'Neil hold after the reported transaction?

After the transaction, Patrick R. O'Neil directly holds 72,359 shares of Ionis common stock. This total includes the 376 shares acquired on February 27, 2026, through the company’s employee stock purchase plan, as shown in the Form 4.

When can the newly purchased Ionis (IONS) shares be sold by Patrick O'Neil?

The newly purchased shares may not be sold until August 27, 2026. This sale restriction applies specifically to the 376 shares acquired under the Ionis Amended and Restated 2000 Employee Stock Purchase Plan on February 27, 2026, according to the Form 4 footnote.

What plan was used for Patrick O'Neil’s recent Ionis (IONS) share acquisition?

The acquisition was made under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan. This plan allows eligible employees, including executives, to purchase company common stock, as reflected in the February 27, 2026 transaction.

Is Patrick O'Neil’s ownership in Ionis (IONS) direct or indirect after this transaction?

Patrick R. O'Neil’s ownership is reported as direct following this transaction. The Form 4 indicates the nature of ownership as direct, and the 72,359 shares of Ionis common stock are held directly in his name after the reported purchase.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'NEIL PATRICK R.

(Last) (First) (Middle)

2855 GAZELLE COURT

(Street)

CARLSBAD CA 92010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IONIS PHARMACEUTICALS INC [ IONS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP CLO & General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/27/2026		J		376(1)	A	$48.8665	72,359	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on February 27, 2026. These shares may not be sold until August 27, 2026.

	Patrick R. O'Neil	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.